What Baliarda S.A. does

Baliarda S.A. is an Argentine pharmaceutical company founded in 1971 that develops, manufactures, and commercializes pharmaceutical specialties across three product categories: prescription (ambulatory) drugs, specialty drugs for high-complexity indications, and over-the-counter (Venta Libre) medications. The portfolio exceeds 200 products spanning 11 therapeutic areas — psychiatry, neurology, cardiology, gastroenterology, traumatology, rheumatology, gynecology, urology, allergy/respiratory, endocrinology, diabetology, and nutrition — with branded generics as the core and a smaller but strategically important specialty layer covering pulmonary arterial hypertension (Maxtran/Macitentan), prostate cancer (Protenza/Enzalutamide), and kidney cancer (Axin/Axitinib). Manufacturing follows strict quality standards regulated by ANMAT, with Risk Management Plans in place for higher-risk molecules and a dedicated pharmacovigilance department handling adverse-event reporting.

The go-to-market is sales-led and channel-driven. Products are distributed through pharmacy networks in Argentina and through subsidiary or commercial-partner operations in seven additional Latin American countries: Bolivia, Chile, Ecuador, Guatemala, Paraguay, the Dominican Republic, and Uruguay. The company targets healthcare professionals (physicians and pharmacists) as the primary demand-shaping channel via medical detailing, while specialty drug patients are supported through the Programa Cercanía wraparound program that provides treatment guidance, medication access support, adherence education, and patient-association referral.

The business model is straightforward pharmaceutical product sales — one-time unit sales through retail pharmacy and partner channels — with no disclosed SaaS, licensing, or recurring-revenue components. The company is privately held, headquartered in Buenos Aires (Cochabamba 2525, CABA), with 501-1,000 employees, and is compliant with Argentina's Personal Data Protection Law 25.326. No revenue, funding, M&A, or leadership data is publicly disclosed.

Name

Baliarda S.A.

Legal name

Baliarda S.A.

Website

https://baliarda.com.ar

Company type

Private

Founded year

1971

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Baliarda S.A. is a Buenos Aires-based pharmaceutical company founded in 1971 that develops, manufactures, and distributes 200+ branded-generic, specialty, and OTC drugs across 11 therapeutic areas, sold through pharmacy channels in Argentina and 7 other Latin American countries.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Gastroenterology & Hepatology Pharmaceuticals (HLAIAAAI), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Specialty drugs
• Over-the-counter medicines
• Pharmacovigilance services

Headquarters

HQ city

San Cristobal

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Baliarda generates revenue through the manufacturing and commercialization of pharmaceutical products including prescription drugs (ambulatory), specialty drugs (treatments specials), and over-the-counter (OTC) drugs. Products are sold through pharmacy distribution channels in Argentina and exported to 8 countries in Latin America.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Baliarda S.A. develops, manufactures, and commercializes pharmaceutical specialties, medicines, and drugs across three main product categories: prescription drugs (ambulatory), specialty drugs (high-complexity treatments for pulmonary arterial hypertension, prostate cancer, and kidney cancer), and over-the-counter (OTC) consumer health products. The portfolio spans 200+ products across 11 therapeutic areas including psychiatry, neurology, cardiology, gastroenterology, traumatology, rheumatology, gynecology, urology, allergy/respiratory, endocrinology, diabetology, and nutrition. The company also provides pharmacovigilance services and a patient support program (Programa Cercanía) for specialty medication patients.

Product overview

Baliarda S.A. is an Argentine pharmaceutical company established in 1971 that develops and manufactures pharmaceutical products. The company operates three main product categories: (1) Prescription Drugs (Outpatient/Ambulatorio) - a comprehensive portfolio of over 130 branded generic medications across therapeutic areas including psychiatry, neurology, cardiology, gastroenterology, traumatology, rheumatology, gynecology, urology, allergy/respiratory, endocrinology, diabetology, and nutrition; (2) Specialty Drugs (Tratamientos Especiales) - high-complexity medications for pulmonary arterial hypertension (Maxtran/Macitentan), prostate cancer (Protenza/Enzalutamide), and kidney cancer (Axin/Axitinib); (3) Over-the-Counter Drugs (Venta Libre) - consumer health products including allergy medications (Alertial 120), digestive products (Pantus 20/40, Pantusec 20/40, Sarmec 20/40), joint health supplements (Biomag, Flepax). The product portfolio is organized by therapeutic lines: Psychiatry, Neurology, Cardiology, Cardiology & Metabolism, Gastroenterology, Traumatology & Rheumatology, Gynecology, Urology, and ATB-Allergy-Respiratory. New product launches include Mirabrol (Mirabegron for overactive bladder), Brexan (Brexpiprazole), Brilep (Brivaracetam), Eudon AE, Axin, Protenza, Maxtran, and others. The company also offers the Programa Cercanía, a patient support program for specialty medication patients, and pharmacovigilance services for adverse event reporting.

Differentiator

Problem solved

Functional benefit

Brands

• Programa Cercanía: Patient support program for special treatment medications providing guidance on accessing medication, treatment adherence support, and patient education

Products and services

• Prescription Drugs (Outpatient/Ambulatorio) Comprehensive portfolio of branded generic prescription medications across 11 therapeutic areas. Distributed through pharmacy networks in Argentina and 7 other Latin American countries. Requires medical authorization for dispensing.
• Specialty Drugs (Tratamientos Especiales) High-complexity medications for serious conditions including Maxtran (Macitentan) for pulmonary arterial hypertension, Protenza (Enzalutamide) for prostate cancer, and Axin (Axitinib) for kidney cancer. Distributed through the Programa Cercanía patient support program with comprehensive treatment guidance and adherence support.
• Over-the-Counter Drugs (Venta Libre) Consumer health products including Alertial 120 (Fexofenadine for allergies), Pantus 20/40 and Pantusec 20/40 (Pantoprazole for reflux), Sarmec 20 (Esomeprazole for reflux), Biomag (Magnesium bisglycinate supplement), and Flepax (Type II Collagen/Vitamin D3 for joint health). Available for direct purchase at pharmacies.
• Programa Cercanía (Patient Support Program) Patient support program providing guidance on medication access, treatment adherence support, educational materials, and connections to patient associations for patients on specialty drug treatments including pulmonary arterial hypertension, prostate cancer, and kidney cancer.
• Pharmacovigilance Services Pharmacovigilance inquiry section for adverse event reporting and product safety monitoring, available to healthcare professionals and patients, conducted in accordance with ANMAT regulations.

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• ANMAT (National Administration of Medicines, Food and Medical Technology)coreOthersRegulatory partnership with Argentina's national medicines authority. All Baliarda products are approved and regulated by ANMAT. The company complies with ANMAT requirements including Risk Management Plans (RMPs) for certain products. Pharmacovigilance activities are conducted in accordance with ANMAT regulations.
• Subsidiaries in Latin AmericacoreChannel Partner/ Reseller/ DistributorBaliarda operates through subsidiaries and commercial partners in 8 countries: Bolivia, Chile, Ecuador, Guatemala, Paraguay, Dominican Republic, and Uruguay. These subsidiaries handle local distribution and commercialization of Baliarda pharmaceutical products in their respective markets.
• Patient AssociationsminorStrategic or Co-development PartnerBaliarda's Programa Cercanía connects patients with relevant patient associations that offer information, resources, and support networks for individuals dealing with specific conditions including pulmonary arterial hypertension, prostate cancer, and kidney cancer.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Baliarda S.A.